FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2987287046> ?p ?o ?g. }

• W2987287046 endingPage "4476" @default.
• W2987287046 startingPage "4476" @default.
• W2987287046 abstract "Background: Patients with lymphoma and myeloma undergoing autologous hematopoietic stem cell transplantation (ASCT) are at risk for mobilization failure, defined as the inability to harvest the minimum recommended 2x106/kg CD34+ cells prior to conditioning. This limitation can be surpassed by combining multiple apheresis sessions, cryopreservation and adding plerixafor to filgrastim. However, these strategies substantially increase transplant costs and are unaffordable for many patients in low and middle-income countries (LMIC). Furthermore, standard doses of plerixafor can lead to unnecessarily high CD34+ cell yields, leading to resource waste. We have previously shown that a reduced dose of plerixafor at 0.12 μg/kg is effective in a pilot trial. Consequently, we have incorporated RD-plerixafor to a mobilization algorithm using peripheral CD34+ cell analysis to be used in a setting with limited resources. Objective: To evaluate the efficacy of a decision-making mobilization algorithm in patients with lymphoma or myeloma defined by our ability to harvest at least 2x106Kg CD34+ cells in a single apheresis session. Methods: We performed a single-arm prospective study including consecutive adults diagnosed with lymphoma or myeloma undergoing ASCT in our institution. Patients received a mobilization regimen consisting of filgrastim 5 μg/kg BID for 4 days. On day 4 peripheral blood CD34+ cell flow cytometry analysis was performed. We designed a mobilization algorithm hypothesizing that if the day 4 CD34+ pre-count was 5-10 cells/μL, a single RD-plerixafor dose at 0.12 mg/kg (11 hours prior to apheresis) would be sufficient to achieve a successful harvest (≥2x106/kg CD34+) in one large-volume apheresis session based on a prior local study (Panel B). Patients with <5 cells/μL received filgrastim plus a single dose of plerixafor 0.24 mg/kg and those with ≥10 cells/μL received filgrastim alone. Plerixafor vials were shared between 2 patients when possible. Day 5 peripheral CD34+ cell analysis was also performed. Cells were not frozen but were stored at 4ºC. Adverse effects, final CD34+ yield and probability of engraftment using 1-survival Kaplan Meier analysis were determined. This study was performed in accordance to the Declaration of Helsinki. Results: Twenty-nine patients were included. Baseline characteristics and outcomes are shown in Table 1. Median day 4 CD34+ cell pre-count was 15 cells/μL (range, 1.4-88.7). Following our algorithm n=19 patients received filgrastim (65.5%), n=6 received RD-plerixafor (20.7%) and n=4 full-dose plerixafor (13.8%). Median day 5 peripheral blood CD34+ increased to 34.3 cells/μL (range, 10.8-107) (Wilcoxon signed ranked p<0.001), with a median increase of +28 cells/μL (+16.77-55.8) in the RD-plerixafor group. No severe adverse events were observed. We were able to successfully harvest 89.7% of patients using our algorithm with median final yield of 3.9x106 (1.7-12.3) CD34+cells/kg. Mobilization success rates were 94.7% for patients who recieved filgrastim alone, 83.3% for RD-plerixafor and 75% for full-dose plerixafor-treated patients. Optimal yields (≥5x106/kg) were achieved by 31% of patients using our strategy. Only three required a second apheresis session, and all underwent successful outpatient transplantation. One patient died due to hemorrhagic stroke on day +7. All remaining patients engrafted. Median probability of engraftment was estimated at 12 days for both neutrophils (95% CI 11.4-12.6) and platelets (95% CI 11.1-12.9) (Panel C). Female sex and prior treatment lines (continuous) were significantly associated to plerixafor requirement in a univariate regression analysis. Our strategy led to savings of $22,000 USD by lowering the plerixafor dose alone. Conclusion: Incorporating RD-plerixafor into a mobilization algorithm is a safe and effective strategy that increases access to transplantation in patients with lymphoma and myeloma at risk of harvesting failure. External validation of our decision-making algorithm is warranted. Disclosures Gomez-Almaguer: Amgen: Consultancy, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Teva: Consultancy, Speakers Bureau; Takeda: Consultancy, Speakers Bureau; Celgene: Consultancy, Speakers Bureau." @default.
• W2987287046 created "2019-11-22" @default.
• W2987287046 creator A5000360404 @default.
• W2987287046 creator A5006192694 @default.
• W2987287046 creator A5017047324 @default.
• W2987287046 creator A5028116634 @default.
• W2987287046 creator A5029707297 @default.
• W2987287046 creator A5045967517 @default.
• W2987287046 creator A5057298536 @default.
• W2987287046 creator A5061346316 @default.
• W2987287046 creator A5083338848 @default.
• W2987287046 creator A5084910105 @default.
• W2987287046 date "2019-11-13" @default.
• W2987287046 modified "2023-10-17" @default.
• W2987287046 title "Incorporating Reduced-Dose Plerixafor to a Preemptive Mobilization Algorithm Increases Access to Autologous Transplantation in a Limited-Resource Setting" @default.
• W2987287046 doi "https://doi.org/10.1182/blood-2019-129516" @default.
• W2987287046 hasPublicationYear "2019" @default.
• W2987287046 type Work @default.
• W2987287046 sameAs 2987287046 @default.
• W2987287046 citedByCount "0" @default.
• W2987287046 crossrefType "journal-article" @default.
• W2987287046 hasAuthorship W2987287046A5000360404 @default.
• W2987287046 hasAuthorship W2987287046A5006192694 @default.
• W2987287046 hasAuthorship W2987287046A5017047324 @default.
• W2987287046 hasAuthorship W2987287046A5028116634 @default.
• W2987287046 hasAuthorship W2987287046A5029707297 @default.
• W2987287046 hasAuthorship W2987287046A5045967517 @default.
• W2987287046 hasAuthorship W2987287046A5057298536 @default.
• W2987287046 hasAuthorship W2987287046A5061346316 @default.
• W2987287046 hasAuthorship W2987287046A5083338848 @default.
• W2987287046 hasAuthorship W2987287046A5084910105 @default.
• W2987287046 hasBestOaLocation W29872870461 @default.
• W2987287046 hasConcept C126322002 @default.
• W2987287046 hasConcept C129470790 @default.
• W2987287046 hasConcept C13373296 @default.
• W2987287046 hasConcept C141071460 @default.
• W2987287046 hasConcept C143998085 @default.
• W2987287046 hasConcept C170493617 @default.
• W2987287046 hasConcept C2776364478 @default.
• W2987287046 hasConcept C2776694085 @default.
• W2987287046 hasConcept C2776738589 @default.
• W2987287046 hasConcept C2777767877 @default.
• W2987287046 hasConcept C2778828106 @default.
• W2987287046 hasConcept C2779050716 @default.
• W2987287046 hasConcept C2779171977 @default.
• W2987287046 hasConcept C2781413609 @default.
• W2987287046 hasConcept C2911091166 @default.
• W2987287046 hasConcept C71924100 @default.
• W2987287046 hasConcept C89560881 @default.
• W2987287046 hasConceptScore W2987287046C126322002 @default.
• W2987287046 hasConceptScore W2987287046C129470790 @default.
• W2987287046 hasConceptScore W2987287046C13373296 @default.
• W2987287046 hasConceptScore W2987287046C141071460 @default.
• W2987287046 hasConceptScore W2987287046C143998085 @default.
• W2987287046 hasConceptScore W2987287046C170493617 @default.
• W2987287046 hasConceptScore W2987287046C2776364478 @default.
• W2987287046 hasConceptScore W2987287046C2776694085 @default.
• W2987287046 hasConceptScore W2987287046C2776738589 @default.
• W2987287046 hasConceptScore W2987287046C2777767877 @default.
• W2987287046 hasConceptScore W2987287046C2778828106 @default.
• W2987287046 hasConceptScore W2987287046C2779050716 @default.
• W2987287046 hasConceptScore W2987287046C2779171977 @default.
• W2987287046 hasConceptScore W2987287046C2781413609 @default.
• W2987287046 hasConceptScore W2987287046C2911091166 @default.
• W2987287046 hasConceptScore W2987287046C71924100 @default.
• W2987287046 hasConceptScore W2987287046C89560881 @default.
• W2987287046 hasIssue "Supplement_1" @default.
• W2987287046 hasLocation W29872870461 @default.
• W2987287046 hasOpenAccess W2987287046 @default.
• W2987287046 hasPrimaryLocation W29872870461 @default.
• W2987287046 hasRelatedWork W1895328588 @default.
• W2987287046 hasRelatedWork W2044838295 @default.
• W2987287046 hasRelatedWork W2106084785 @default.
• W2987287046 hasRelatedWork W2154836716 @default.
• W2987287046 hasRelatedWork W2548609368 @default.
• W2987287046 hasRelatedWork W2591537899 @default.
• W2987287046 hasRelatedWork W2615190768 @default.
• W2987287046 hasRelatedWork W2750897134 @default.
• W2987287046 hasRelatedWork W3176989103 @default.
• W2987287046 hasRelatedWork W3211271500 @default.
• W2987287046 hasVolume "134" @default.
• W2987287046 isParatext "false" @default.
• W2987287046 isRetracted "false" @default.
• W2987287046 magId "2987287046" @default.
• W2987287046 workType "article" @default.